
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4824D8AEED0D305824D00553BEA05.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="bmccanc">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376434/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="BMC Cancer">
<meta name="citation_title" content="The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy">
<meta name="citation_author" content="Hui Wu">
<meta name="citation_author_institution" content="Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 China">
<meta name="citation_author" content="Wenzhi Shu">
<meta name="citation_author_institution" content="Zhejiang University School of Medicine, Hangzhou, China">
<meta name="citation_author" content="Yongfeng Ding">
<meta name="citation_author_institution" content="Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 China">
<meta name="citation_author" content="Qiong Li">
<meta name="citation_author_institution" content="Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 China">
<meta name="citation_author" content="Ning Li">
<meta name="citation_author_institution" content="Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 China">
<meta name="citation_author" content="Qiyue Wang">
<meta name="citation_author_institution" content="Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 China">
<meta name="citation_author" content="Yinqi Chen">
<meta name="citation_author_institution" content="Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 China">
<meta name="citation_author" content="Yuejun Han">
<meta name="citation_author_institution" content="Zhejiang University School of Medicine, Hangzhou, China">
<meta name="citation_author" content="Dongdong Huang">
<meta name="citation_author_institution" content="Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou, China">
<meta name="citation_author" content="Haiping Jiang">
<meta name="citation_author_institution" content="Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 China">
<meta name="citation_publication_date" content="2025 Aug 25">
<meta name="citation_volume" content="25">
<meta name="citation_firstpage" content="1369">
<meta name="citation_doi" content="10.1186/s12885-025-14805-6">
<meta name="citation_pmid" content="40851062">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376434/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376434/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376434/pdf/12885_2025_Article_14805.pdf">
<meta name="description" content="Anti-programmed cell death-1 (PD-1) immunotherapy and platinum-based chemotherapy are key components of first-line treatment for advanced Gastric or Gastroesophageal Junction (G/GEJ) cancer. However, the role of immune cells infiltrating the tumor ...">
<meta name="og:title" content="The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Anti-programmed cell death-1 (PD-1) immunotherapy and platinum-based chemotherapy are key components of first-line treatment for advanced Gastric or Gastroesophageal Junction (G/GEJ) cancer. However, the role of immune cells infiltrating the tumor ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376434/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12376434">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s12885-025-14805-6"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/12885_2025_Article_14805.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12376434%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12376434/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12376434/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376434/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-bmccanc.png" alt="BMC Cancer logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to BMC Cancer" title="Link to BMC Cancer" shape="default" href="https://doi.org/10.1186/s12885-025-14805-6" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">BMC Cancer</button></div>. 2025 Aug 25;25:1369. doi: <a href="https://doi.org/10.1186/s12885-025-14805-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s12885-025-14805-6</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22BMC%20Cancer%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22BMC%20Cancer%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22BMC%20Cancer%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22BMC%20Cancer%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wu%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Hui Wu</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Hui Wu</span></h3>
<div class="p">
<sup>1</sup>Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wu%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hui Wu</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shu%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Wenzhi Shu</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Wenzhi Shu</span></h3>
<div class="p">
<sup>2</sup>Zhejiang University School of Medicine, Hangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shu%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Wenzhi Shu</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ding%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Yongfeng Ding</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Yongfeng Ding</span></h3>
<div class="p">
<sup>1</sup>Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ding%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yongfeng Ding</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Qiong Li</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Qiong Li</span></h3>
<div class="p">
<sup>1</sup>Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qiong Li</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Ning Li</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Ning Li</span></h3>
<div class="p">
<sup>1</sup>Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Ning Li</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Qiyue Wang</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Qiyue Wang</span></h3>
<div class="p">
<sup>1</sup>Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qiyue Wang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Yinqi Chen</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Yinqi Chen</span></h3>
<div class="p">
<sup>1</sup>Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yinqi Chen</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Han%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Yuejun Han</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Yuejun Han</span></h3>
<div class="p">
<sup>2</sup>Zhejiang University School of Medicine, Hangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Han%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yuejun Han</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Dongdong Huang</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Dongdong Huang</span></h3>
<div class="p">
<sup>3</sup>Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dongdong Huang</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jiang%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Haiping Jiang</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Haiping Jiang</span></h3>
<div class="p">
<sup>1</sup>Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jiang%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Haiping Jiang</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310006 China </div>
<div id="Aff2">
<sup>2</sup>Zhejiang University School of Medicine, Hangzhou, China </div>
<div id="Aff3">
<sup>3</sup>Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou, China </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Jun 9; Accepted 2025 Aug 4; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12376434  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40851062/" class="usa-link">40851062</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p id="Par1">Anti-programmed cell death-1 (PD-1) immunotherapy and platinum-based chemotherapy are key components of first-line treatment for advanced Gastric or Gastroesophageal Junction (G/GEJ) cancer. However, the role of immune cells infiltrating the tumor microenvironment (TME) in predicting both therapy responses is still unclear.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">ORIENT-16 is a randomized, double-blind, placebo-controlled, phase 3 clinical trial, and enrolled 650 patients with unresectable locally advanced or metastatic G/GEJ cancer between January 3, 2019, and August 5, 2020. For patients enrolled from the First Affiliated Hospital of Zhejiang University School of Medicine, we analyzed progression-free survival(PFS) and overall survival (OS) based on PD-L1 expression and landmark analysis, and developed a multiplexed immunofluorescence (mIF) assay for CD4, CD8, PD-L1, CD68 and FoxP3 coupled with digital image analysis and machine learning to assess prognostic survival associations of immune cells.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">A total of 54 eligible patients were enrolled in this study, 35 received sintilimab plus platinum-based chemotherapy and 19 received placebo plus platinum-based chemotherapy. For patients with PD-L1 combined positive score (CPS) &lt; 10, survival disparities between anti-PD-1 immunotherapy and chemotherapy emerged 300 days post-treatment. High PD-L1 expression correlated with longer survival in anti-PD-1 therapy but less benefit in platinum-based chemotherapy. The mIF analysis also demonstrated significantly higher stromal PD-L1 density in immunotherapy responders, but tended to be lower in chemotherapy responders. Besides, high tumor stromal CD8 expression could be used as a positive biomarker in anti-PD-1 immunotherapy, and high tumor stromal CD4 expression was found associated with worse prognosis in platinum-based chemotherapy.</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusions</h3>
<p id="Par4">Increased PD-L1 expression was associated with an increased effect on anti-PD-1 immunotherapy and reduced benefit from chemotherapy. The signature of TME immune cells has the potential to predict the response of anti-PD-1 immunotherapy and chemotherapy in G/GEJ cancer.</p></section><section id="sec5"><h3 class="pmc_sec_title">Trial registration</h3>
<p id="Par5">ClinicalTrials.gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT03745170" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03745170</a>.</p></section><section id="sec6"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1186/s12885-025-14805-6.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Gastric/Gastroesophageal junction (G/GEJ) cancer, Anti-PD-1 blockade, Platinum-based chemotherapy, Tumor immune microenvironment (TME), Predictive biomarkers</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par35">Gastric and gastroesophageal junction (G/GEJ) cancer is one of the most common cancers worldwide, ranking fifth in incidence and fourth in mortality [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. In China, new G/GEJ cancer cases account for approximately 40% of all new cases globally, with the vast majority presenting at stage III or IV and missing the opportunity for surgical resection [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>, <a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. Even after curative surgery, most patients develop local recurrence or distant metastases, with a 5-year survival rate of less than 25% [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>–<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>].</p>
<p id="Par36">Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) have significantly revolutionized the treatment landscape of advanced G/GEJ cancers [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>, <a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>]. The ORIENT-16 trials [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>] demonstrated superior efficacy and safety of first-line sintilimab plus chemotherapy compared to chemotherapy alone in Chinese patients. However, no significant differences were observed for patients with a combined positive score (CPS) less than 5. It seems that not all G/GEJ patients could benefit from inhibitors. The predictive value of PD-L1 in precision medicine remains to be explored. In addition, as the cornerstone treatment modality, fluoropyrimidine plus platinum-based chemotherapy is still an indispensable strategy for unresectable advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative G/GEJ adenocarcinoma, but its clinical outcome is far from satisfactory [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>–<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. Therefore, there is an urgent need to study the potential factors that affect anti-PD-1/PD-L1 immunotherapy and platinum-based chemotherapy.</p>
<p id="Par37">Alongside a growing understanding of the tumor immune microenvironment, researchers are increasingly focusing on components that may influence the treatment response, such as T cells, B cells, neutrophils, and macrophages [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>–<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. In this context, studies have suggested that a high abundance of infiltrating CD8 + or CD3 + T cells within tumor tissues indicates a neoplastic “hot tumor” or an immune-inflamed state, suggesting a robust immune response [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]. PD-1 and PD-L1 blockade can also elicit a strong natural killer (NK) cell response [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>], whereas β-catenin within the tumor can hinder dendritic cell recruitment, leading to PD-1/PD-L1 resistance [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. The immune status of an individual can also be used to assess the effects of chemotherapy. Recent advances highlight the TME’s multidimensional role in therapy resistance. Machine learning frameworks like iMLGAM [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>], DAS [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>], and PTMLS [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>], driven by multiomics-defined features such as post-translational modified proteins and tumor-related genes, revealed that immune-hot microenvironments correlate with superior ICB response. These underscore the need for composite biomarker strategies. Therefore, owing to the inherent heterogeneity of tumors and the complex immune response to treatment, single biomarkers are insufficient for identifying the potential benefits in gastric cancer treatments.</p>
<p id="Par38">Advancements in multiplex immunofluorescence (mIF) allow simultaneous visualization of multiple antigen markers within the same tissue section. This technique, combined with digital image analysis and machine learning, facilitates characterization of the density and spatial distribution of the tumor immune microenvironment. However, mIF remains underutilized in the context of advanced gastric cancer. Consequently, factors within the tumor microenvironment that dictate the response to first-line anti-PD-1 immunotherapy and chemotherapy remain unclear.</p>
<p id="Par39">In the present study, patients in the ORIENT-16 study from the First Affiliated Hospital of Zhejiang University School of Medicine were included. We further analyzed the survival curves using the landmark statistical method and performed exploratory analyses of the efficacy of anti-PD-1 immunotherapy and platinum-based chemotherapy in PD-L1 CPS ≥ 10 and CPS &lt; 10 subgroups. Using multiplexed immunofluorescence combined with digital image analysis and supervised machine learning, we quantified the immune cells in the tumor microenvironment and assessed the relationship between immune cell densities and treatment outcomes. These data will be used to investigate the immune and stromal features of good responders and poor responders, with the goal of identifying the prognostic significance of immune biomarkers of anti-PD-1 immunotherapy or platinum-based chemotherapy.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Study design and participants</h3>
<p id="Par40">The ORIENT-16 study, a randomized, double-blind, phase 3 clinical trial, was conducted at 62 hospitals in China and registered on November 14, 2018, at ClinicalTrials.gov (<a href="https://clinicaltrials.gov/ct2/show/NCT03745170" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03745170</a>) (<a href="https://www.clinicaltrials.gov/ct2/show/NCT03745170?term=NCT03745170%26;draw=2%26;rank=1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/ct2/show/NCT03745170?term=NCT03745170%26;draw=2%26;rank=1</a>). Our study is a secondary analysis of data from the ORIENT-16 study. Patients from the First Affiliated Hospital of Zhejiang University School of Medicine were collected, which has the largest number of participants in the ORIENT-16 study. The trial was conducted according to Good Clinical Practice Guideline. The protocol and all amendments were approved by an independent ethics committee and were consistent with the ORIENT-16 study published previously [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>].</p>
<p id="Par41">Eligible patients were 18 years or older with histologically confirmed unresectable locally advanced, recurrent, or metastatic G/GEJ adenocarcinoma. Patients who had received previous adjuvant or neoadjuvant chemotherapy or radiotherapy were also allowed at least 6 months after the last administration for disease recurrence. Additionally, patients needed to have at least one measurable or evaluable lesion, as defined in the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1). Patients with known human epidermal growth factor receptor 2 (HER2)-positive status; a history of active, known, or suspected autoimmune disease; or prior systemic treatment for advanced or metastatic G/GEJ adenocarcinoma were excluded from the trial. Written informed consent was obtained from all patients prior to enrollment.</p>
<p id="Par42">All patients were randomly assigned to sintilimab plus chemotherapy group (sintilimab plus platinum-based chemotherapy) and placebo plus chemotherapy group (placebo plus platinum-based chemotherapy). Randomization was performed using an interactive web response system and stratified according to the Performance Status (PS) score of the Eastern Cooperative Oncology Group Performance Status (ECOG) (0 or 1), liver metastasis (yes or no), peritoneum metastasis (yes or no), and PD-L1 (Combined Positive Score (CPS) &lt; 10 or ≥ 10). The patients, investigators, and study sponsor remained blinded to the treatment assignment throughout the study.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Outcomes</h3>
<p id="Par43">The primary endpoints of overall survival (OS) and the secondary endpoints of progression-free survival (PFS), objective response rate (ORR) and safety for the primary analysis populations of ORIENT-16—the total, PD-L1 CPS ≥ 5, and CPS &lt; 5 populations—have been reported. The efficacy outcomes for the PD-L1 CPS &lt; 10 and CPS ≥ 10 subgroups (OS and PFS) were evaluated. Additionally, the prespecified exploratory endpoint evaluated the association between the efficacy of anti-PD-1 immunotherapy or platinum-based chemotherapy and PD-L1 expression levels as well as other biomarkers within the immune microenvironment. The efficacy endpoints were assessed by independent reviewers.</p></section><section id="Sec5"><h3 class="pmc_sec_title">Biomarker analysis</h3>
<p id="Par44">
Formalin-fixed, paraffin-embedded samples from primary or metastatic lesions were evaluated during screening for PD-L1 expression. The evaluation was performed by a central laboratory (Covance, Shanghai, China) using PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies, USA). A scoring system called the combined positive score (CPS) was used, which was obtained by dividing the number of PD-L1-positive tumor cells, lymphocytes, and macrophages by the total number of viable tumor cells, and then multiplying by 100.</p>
<p id="Par45">Based on the abundant literature on the modulatory effects of the tumor microenvironment, the research team decided on a biomarker panel after further discussion. This panel included T cells (CD4 [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>], CD8 [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]), regulatory T cells (FoxP3 [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]), macrophages (CD68 [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]), immune escape markers (PD-L1 [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>]), and Pan-CK. The Akoya OPAL Polaris Seven-Color Automation multiplex immunohistochemistry (mIHC) panels were used for mIF staining following the manufacturer’s instructions. The concentration and staining order of the antibodies used in this study were optimized in advance. Primary antibodies raised against CD4 (Cell Signaling Technology, #25229, 1:50), CD8 (Cell Signaling Technology, #85336, 1:100), CD68 (Cell Signaling Technology, #76437, 1:200), FoxP3 (Cell Signaling Technology, #98377, 1:50), and PD-L1 (Cell Signaling Technology, #13684, 1:100), were used. Nucleic acids were stained with DAPI. Tumor parenchyma and stroma were differentiated based on pan-CK staining (Cell Signaling Technology, #4545, 1:250).</p>
<p id="Par46">
The immunofluorescence slides were scanned using the Vectra 3.0 Automated Quantitative Pathology Imaging System (Akoya Biosciences) equipped with a 20 × objective and visualized using Phenochart software. Two experienced pathologists reviewed all samples and excluded inappropriate regions from the analysis. Typical fields of view were selected with minimal overlap between regions and positioned to capture as much tissue as possible. The multispectral images were analyzed using the inForm software package(Akoya Biosciences). The density of various immune cell subsets was measured as the number of positively stained cells per square millimeter (cells/mm<sup>2</sup>).</p></section><section id="Sec6"><h3 class="pmc_sec_title">Statistical analyses</h3>
<p id="Par47">Statistical analyses were performed using GraphPad Prism 9 and the IBM SPSS Statistics software (version 26.0). The chi-square test or Independent Samples t-test was performed to compare the baseline characteristics between the two treatment arms. Censoring for overall survival and progression-free survival occurred at the last date of survival and last tumor imaging assessment, respectively. Kaplan-Meier (KM) plots were generated to visualize the corresponding PFS and OS, and the stratified log-rank test was used to compare the treatment arms (sintilimab + chemotherapy vs. placebo + chemotherapy) and CPS score groups (≥ 10 vs. &lt;10). Two-sided 95% confidence intervals (CIs) for the hazard ratios (HRs) were calculated. Subgroup analyses using the stratified Cox proportional hazards model assessed PFS and OS according to CPS scores and baseline characteristics (age, histological type, and metastases), ensuring a minimum sample size of 15 per subgroup. The independent sample t-test and Mann-Whitney U test were used to assess the association between immune cells in tumor microenvironment and treatment efficacy in the exploratory multiplexed immunofluorescence analysis.</p></section></section><section id="Sec7"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec8"><h3 class="pmc_sec_title">Patients characteristics</h3>
<p id="Par48">
From January 3, 2019, to July 20, 2020, 63 patients were screened for eligibility in our center. Of these, 54 were randomly assigned to treatment: 35 in the sintilimab plus chemotherapy group and 19 in the placebo plus chemotherapy group (Fig. <a href="#Fig1" class="usa-link">1</a>A). The baseline characteristics were generally well balanced between the two treatment groups (Table <a href="#Tab1" class="usa-link">1</a>). Among 54 patients, 39 (72.2%) had gastric adenocarcinoma (sintilimab plus chemotherapy, 25/35 [71.4%]; placebo plus chemotherapy, 14/19 [73.7%]). Thirty-seven (68.5%) patients had a PD-L1 CPS ≥ 10 (sintilimab plus chemotherapy, 12/35 [34.3%]; placebo plus chemotherapy, 5/19 [26.3%]). Distant lymph nodes (33/54 [61.1%]) and peritoneal metastases (22/54 [40.7%]) were the most common presentations in patients with advanced disease. Of the patients in the immunotherapy group, 28.6% (<em>n</em> = 10/35) discontinued treatment within the first six cycles, compared to 52.6% (<em>n</em> = 10/19) in the chemotherapy group. Disease progression was the main reason for discontinuation (sintilimab plus chemotherapy, 5/35 [14.3%]; placebo plus chemotherapy, 6/19 [31.6%]). 65.7% (<em>n</em> = 23/35) of the patients in the sintilimab plus chemotherapy group, compared to 42.1% (<em>n</em> = 8/19) in the placebo plus chemotherapy group subsequent treatment. Additionally, 14.3% (<em>n</em> = 5/35) and 15.8% (<em>n</em> = 3/19) of the respective groups underwent subsequent gastrectomy. The changes of best reduction from baseline in target leisions, as well as tumor response and some clinical data are presented in a waterfall plot (Fig. <a href="#Fig1" class="usa-link">1</a>B).</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12376434_12885_2025_14805_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b6f/12376434/a85c629b7772/12885_2025_14805_Fig1_HTML.jpg" loading="lazy" id="d33e568" height="694" width="669" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Trial profile (<strong>A</strong>) and treatment response (<strong>B</strong>)</p></figcaption></figure><section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Baseline characteristics of study patients</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">Sintilimab + chemotherapy<sup>a</sup> (<em>N</em> = 35)</th>
<th align="left" colspan="1" rowspan="1">Placebo + chemotherapy (<em>N</em> = 19)</th>
<th align="left" colspan="1" rowspan="1">
<em>P</em>-value</th>
</tr></thead>
<tbody>
<tr><td align="left" colspan="4" rowspan="1">Age (years)</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Median</td>
<td align="left" colspan="1" rowspan="1">62</td>
<td align="left" colspan="1" rowspan="1">63</td>
<td align="left" colspan="1" rowspan="1">0.69</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Range</td>
<td align="left" colspan="1" rowspan="1">41–74</td>
<td align="left" colspan="1" rowspan="1">44–72</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Sex, <em>n</em> (%)</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Female</td>
<td align="left" colspan="1" rowspan="1">9(25.7)</td>
<td align="left" colspan="1" rowspan="1">7(36.8)</td>
<td align="left" colspan="1" rowspan="1">0.39</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Male</td>
<td align="left" colspan="1" rowspan="1">26(74.3)</td>
<td align="left" colspan="1" rowspan="1">12(63.2)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">ECOG performance status, <em>n</em> (%)</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 0</td>
<td align="left" colspan="1" rowspan="1">10(28.6)</td>
<td align="left" colspan="1" rowspan="1">8(42.1)</td>
<td align="left" colspan="1" rowspan="1">0.31</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 1</td>
<td align="left" colspan="1" rowspan="1">25(71.4)</td>
<td align="left" colspan="1" rowspan="1">11(57.9)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Primary tumor location, <em>n</em> (%)</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Gastric</td>
<td align="left" colspan="1" rowspan="1">35(100.0)</td>
<td align="left" colspan="1" rowspan="1">18(94.7)</td>
<td align="left" colspan="1" rowspan="1">0.75</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Gastric-esophageal junction</td>
<td align="left" colspan="1" rowspan="1">0(0.0)</td>
<td align="left" colspan="1" rowspan="1">1(5.3)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Histological type, <em>n</em> (%)</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Adenocarcinoma</td>
<td align="left" colspan="1" rowspan="1">25(71.4)</td>
<td align="left" colspan="1" rowspan="1">14(73.7)</td>
<td align="left" colspan="1" rowspan="1">0.86</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Signet cell carcinoma</td>
<td align="left" colspan="1" rowspan="1">10(28.6)</td>
<td align="left" colspan="1" rowspan="1">5(26.3)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Lauren’s classification, <em>n</em> (%)</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Intestinal</td>
<td align="left" colspan="1" rowspan="1">6(16.7)</td>
<td align="left" colspan="1" rowspan="1">0(0.0)</td>
<td align="left" colspan="1" rowspan="1">0.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Diffuse</td>
<td align="left" colspan="1" rowspan="1">5(14.3)</td>
<td align="left" colspan="1" rowspan="1">3(15.8)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Mixed</td>
<td align="left" colspan="1" rowspan="1">2(5.6)</td>
<td align="left" colspan="1" rowspan="1">3(15.8)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Unknown or unclassifiable</td>
<td align="left" colspan="1" rowspan="1">22(62.9)</td>
<td align="left" colspan="1" rowspan="1">13(68.4)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Previous gastrectomy, <em>n</em> (%)</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">28(80.0)</td>
<td align="left" colspan="1" rowspan="1">16(84.2)</td>
<td align="left" colspan="1" rowspan="1">0.79</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">7(20.0)</td>
<td align="left" colspan="1" rowspan="1">3(15.8)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Perioperative chemotherapy, <em>n</em> (%)</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">31(88.6)</td>
<td align="left" colspan="1" rowspan="1">17(89.5)</td>
<td align="left" colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">4(11.4)</td>
<td align="left" colspan="1" rowspan="1">2(10.5)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Extent of disease, <em>n</em> (%)</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Metastatic</td>
<td align="left" colspan="1" rowspan="1">35(100.0)</td>
<td align="left" colspan="1" rowspan="1">16(84.2)</td>
<td align="left" colspan="1" rowspan="1">0.07</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Locally advanced</td>
<td align="left" colspan="1" rowspan="1">0(0.0)</td>
<td align="left" colspan="1" rowspan="1">3(15.8)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Site of metastases, <em>n</em> (%)</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Liver</td>
<td align="left" colspan="1" rowspan="1">8(22.9)</td>
<td align="left" colspan="1" rowspan="1">7(36.8)</td>
<td align="left" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Peritoneum</td>
<td align="left" colspan="1" rowspan="1">14(40.0)</td>
<td align="left" colspan="1" rowspan="1">8(42.1)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Lung</td>
<td align="left" colspan="1" rowspan="1">2(5.7)</td>
<td align="left" colspan="1" rowspan="1">2(10.5)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Bone</td>
<td align="left" colspan="1" rowspan="1">3(8.6)</td>
<td align="left" colspan="1" rowspan="1">1(5.3)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Lymph node</td>
<td align="left" colspan="1" rowspan="1">22(62.9)</td>
<td align="left" colspan="1" rowspan="1">11(57.9)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Other</td>
<td align="left" colspan="1" rowspan="1">8(22.9)</td>
<td align="left" colspan="1" rowspan="1">6(31.6)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Tumor cell PD-L1 expression</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> CPS &lt; 10</td>
<td align="left" colspan="1" rowspan="1">23(65.7)</td>
<td align="left" colspan="1" rowspan="1">14(73.7)</td>
<td align="left" colspan="1" rowspan="1">0.55</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> CPS ≥ 10</td>
<td align="left" colspan="1" rowspan="1">12(34.3)</td>
<td align="left" colspan="1" rowspan="1">5(26.3)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p25">
<p><em>ECOG</em> Eastern Cooperative Oncology Group, <em>PD-L1</em> Programmed Death-Ligand 1, <em>CPS</em> the Combined Proportional Score</p>
<p><sup>a</sup>Chemotherapy: XELOX(Capecitabine plus oxaliplatin)</p>
</div></div></section></section><section id="Sec9"><h3 class="pmc_sec_title">Survival differences between anti-PD-1 therapy and chemotherapy: subgroup analyses and landmark analyses</h3>
<p id="Par51">The efficacy and safety analyses in the present study were in accordance with ORIENT-16 observations, and each is indicated with a note in the supplementary materials. A CPS threshold of 10 was used as the randomization stratification factor in our study. Patients with a CPS of 10 or more appeared to benefit significantly more from sintilimab immunotherapy, with an estimated hazard ratio (HR) of 0.14 (95% CI 0.02–1.01; <em>P</em> &lt; 0.0001) for PFS and 0.19 (95% CI 0.03–1.09; <em>P</em> = 0.0009) for OS (Fig. <a href="#Fig2" class="usa-link">2</a>A and B). Conversely, no significant benefits were observed in patients with CPS less than 10 (mPFS, HR 0.66 [0.30–1.48]; <em>P</em> = 0.27; OS, HR 0.66 [0.30–1.48]; <em>p</em> = 0.25) (Fig. <a href="#Fig2" class="usa-link">2</a>C and D). Landmark analysis of the CPS &lt; 10 population revealed temporal heterogeneity in treatment response: while early survival curves were comparable (<em>P</em> = 0.632), a statistically significant divergence emerged beyond 300 days post-treatment (<em>P</em> = 0.008; Fig. <a href="#Fig3" class="usa-link">3</a>). Complete subgroup analyses are presented in Supplementary Figs. 2–3.</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12376434_12885_2025_14805_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b6f/12376434/b96b8f2302c9/12885_2025_14805_Fig2_HTML.jpg" loading="lazy" id="d33e980" height="540" width="669" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Kaplan-Meier plot of progression-free survival and overall survival. Progression-free survival in patients with PD-L1 CPS ≥ 10 (<strong>A</strong>) and PD-L1 CPS &lt; 10 (<strong>C</strong>); overall survival in patients with PD-L1 CPS ≥ 10 (<strong>B</strong>) and PD-L1 CPS &lt; 10 (<strong>D</strong>); ✴Small lesions (longest diameter &lt; 10 mm or pathological lymph node short diameter ≥ 10 mm to &lt; 15 mm) were taken as unmeasurable lesions. HR, hazard ratio</p></figcaption></figure><figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12376434_12885_2025_14805_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b6f/12376434/68f9cbe04bac/12885_2025_14805_Fig3_HTML.jpg" loading="lazy" id="d33e990" height="396" width="669" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Survival curves using the LANDMARK method of overall survival</p></figcaption></figure></section><section id="Sec10"><h3 class="pmc_sec_title">Survival analyses of both anti-PD-1 therapy and chemotherapy: predictive role of PD-L1 expression</h3>
<p id="Par54">We performed a comprehensive evaluation of treatment efficacy stratified by PD-L1 expression levels in patients receiving either anti-PD-1 immunotherapy or platinum-based chemotherapy (Fig. <a href="#Fig4" class="usa-link">4</a>A-F). For patients receiving sintilimab, the mPFS was 12.34 months in patients with CPS of 10 or more and 6.47 months in patients with CPS less than 10 (<em>P</em> = 0.13) (Fig. <a href="#Fig4" class="usa-link">4</a>C). Similarly, the mOS also improved in the CPS ≥ 10 group by 9.88 months (23.18 months vs. 13.30 months; HR 0.51 [95% CI: 0.23–1.13]; <em>P</em> = 0.12) (Fig. <a href="#Fig4" class="usa-link">4</a>D). Although these differences did not reach statistical significance, the data suggest a potential clinical benefit of immunotherapy in patients with higher PD-L1 expression.</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12376434_12885_2025_14805_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b6f/12376434/3e552b0b0a94/12885_2025_14805_Fig4_HTML.jpg" loading="lazy" id="d33e1040" height="1016" width="762" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Progression-free survival and overall survival subgroup analysis according to PD-L1 CPS. Progression-free survival in all randomized patients (<strong>A</strong>) and in patients receiving immunotherapy plus chemotherapy (<strong>C</strong>) and placebo plus chemotherapy (<strong>E</strong>). Overall survival in all randomized patients (<strong>B</strong>) and in patients receiving immunotherapy plus chemotherapy (<strong>D</strong>) and placebo plus chemotherapy (<strong>F</strong>). CI, confidence interval; CPS, combined positive score; HR, hazard ratio</p></figcaption></figure><p id="Par56">Conversely, in chemotherapy-alone group, patients with CPS ≥ 10 exhibited a concerning trend toward poorer outcomes. Their mPFS was shorter than the CPS &lt; 10 subgroup (3.40 vs. 4.33 months; <em>P</em> = 0.07) (Fig. <a href="#Fig4" class="usa-link">4</a>E), with a more pronounced reduction in mOS (4.40 vs. 12.67 months; <em>P</em> = 0.11) (Fig. <a href="#Fig4" class="usa-link">4</a>F). This exploratory analysis suggests that patients with high PD-L1 expression may be insensitive to platinum-based chemotherapy and highlights the need for PD-L1-guided treatment selection in G/GEJ cancer management.</p></section><section id="Sec11"><h3 class="pmc_sec_title">Relationships with TME immune cell subtypes and both anti-PD-1 therapy and chemotherapy: multiplex Immunofluorescence analyses</h3>
<p id="Par57">To further explore whether the tumor immune microenvironment could predict the treatment response, biopsy samples of all patients collected before treatment were analyzed separately by multiplex immunofluorescence. Patients with no tumor progression within half a year were defined as well-responders, and those with tumor progression were defined as poor-responders. Among 54 initially enrolled patients, 33 baseline samples met quality control criteria and were included in the final analysis (sintilimab plus chemotherapy group, <em>n</em> = 18; placebo plus chemotherapy group, <em>n</em> = 15).</p>
<p id="Par58">In patients receiving anti-PD-1 immunotherapy (Fig. <a href="#Fig5" class="usa-link">5</a>A), patients in the well-responder group showed higher densities of PD-L1 expression than those in the poor-responder group (<em>P</em> = 0.02). Interestingly, a strong positive association between CD8 + T cell infiltration and treatment response were revealed in our mIF analysis, with well-responders demonstrating higher CD8 + T cell densities (<em>P</em> = 0.04), whereas there were no major differences in CD4 + T cells, CD68 + macrophages, or Foxp3 + regulatory T cells (Tregs) between the well-responder and poor-responder groups, both in the context of tumor and stromal cells (Fig. <a href="#Fig5" class="usa-link">5</a>B).</p>
<figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12376434_12885_2025_14805_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b6f/12376434/1d18785eb69e/12885_2025_14805_Fig5_HTML.jpg" loading="lazy" id="d33e1101" height="807" width="669" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The merged and single-stained images for four representative multiplex immunofluorescence (mIF) of tumor microenvironment (TME). Typical mIF images of a patient receiving sintilimab plus chemotherapy (<strong>A</strong>) and placebo plus chemotherapy (<strong>D</strong>). Immune cell infiltration levels in the tumor tissue before sintilimab plus chemotherapy (<strong>B</strong>) and placebo plus chemotherapy (<strong>C</strong>) between patients in the well-responder group and those in the poor-responder group assessed by multiplex immunofluorescence (mIF). Scale bar:100 μm</p></figcaption></figure><p id="Par60">Notably, as shown in Fig. <a href="#Fig5" class="usa-link">5</a>C, in patients receiving platinum-based chemotherapy alone, the number of CD4 + T cells was significantly higher in patients with poor chemotherapeutic efficacy (<em>P</em> = 0.03). Similarly, the expression levels of PD-L1 in the poor-responder group were also higher than those in the well-responder group (<em>P</em> = 0.07), consistent with our results of clinical analysis, although not reaching statistical significance limited by the small sample size (Fig. <a href="#Fig5" class="usa-link">5</a>D). However, no differential expression patterns were detected for CD8 + T cells, CD68 + macrophages, or FoxP3 + Tregs in chemotherapy-treated patients.</p></section></section><section id="Sec12"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par61">In recent years, immunotherapy for advanced G/GEJ cancer has attracted widespread attention. Prospective clinical trials, such as CheckMate 649 [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>], ORIENT-16 [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>], and RATIONALE 305 [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>] have demonstrated an effective clinical response in patients with advanced HER2-negative gastric cancer. Our results, consistent with the results of the ORIENT-16 study, further demonstrate the efficacy and safety of adding anti-PD-1 sintilimab to platinum-based chemotherapy, which resulted in a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival compared to chemotherapy alone, not only in the overall population but also in patients with strong PD-L1 expression.</p>
<p id="Par62">However, the efficacy of anti-PD-1 treatment in tumors with low PD-L1 expression remains unclear. The results of patients with a CPS less than 5 have been shown to have a non-significant survival benefit in the ORIENT-16 study. The level of PD-L1 expression was reclassified and two PD-L1 subgroups (CPS &lt; 10 and CPS ≥ 10) were identified in our study, finding that for patients with CPS less than 10, no significant difference was observed between the anti-PD-1 immunotherapy plus chemotherapy group and placebo plus chemotherapy group (<em>P</em> = 0.761). This observation aligns with Zhao et al.‘s findings [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>], which demonstrated no significant differences in OS and PFS between ICI-chemotherapy combinations and chemotherapy alone in the CheckMate-649 PD-L1 CPS 1–4 and KEYNOTE-062 PD-L1 CPS 1–9 subgroups (<em>P</em> ≥ 0.05). Interestingly, our landmark analysis identified a delayed survival advantage emerging approximately 300 days post-treatment in low PD-L1 expressors (CPS &lt; 10) receiving ICI-chemotherapy combination therapy. This long-term survival discrepancy is likely attributable to the tailing effect of anti-PD-L1 treatment, wherein sustained immune activation through tumor-immune interactions and memory T cell formation drives prolonged clinical benefit, as opposed to the direct cytotoxic mechanism of chemotherapy. Supporting this interpretation, Gauci et al. [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>] conducted a long-term analysis of solid tumor patients responding to anti-PD-1/PD-L1 therapy and found that 48/76 patients developed an objective response at 3 months regardless of PD-L1 expression. Similarly, the tailing effect, which depends on the immune status of an individual and tumor heterogeneity, was also embodied in long-term follow-up data of some clinical trials such as CheckMate153 of NSCLC [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>] and RATIONALE-305 [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>] of advanced GC, especially striking in patients with high PD-L1 expression. This conclusion has also been validated in patients with CPS &lt; 10 in our study and a time point of 300 days was proposed. Moreover, consolidation chemotherapy was initiated after six cycles of combination therapy in both groups and continued for up to a maximum of 2 years. Therefore, we proposed an alternative hypothesis that applications of immunotherapy might increase the sensitivity of the tumor to subsequent chemotherapy. Exposure to immune checkpoint inhibitors may elicit the antitumor activity of chemotherapy, which can lead to a high response rate [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]. A retrospective CLARITY study [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>] also supported that for NSCLC patients who progressed to previous ICIs administered as first- or second-line therapy, salvage chemotherapy could yield a survival-favorable response. While the precise mechanisms require further elucidation, these findings have important clinical implications: For CPS &lt; 10 patients with limited life expectancy, early combination therapy may offer restricted benefit; For most patients, immunotherapy should be initiated as early as possible in the treatment course and could be continued as maintenance therapy after 4–6 cycles of complete routine first-line therapy, and disease control (CR/PR/SD) was reached in order to increase the survival benefit.</p>
<p id="Par63">In addition, we found that only a subset of patients could benefit from anti-PD-1 immunotherapy or platinum-based chemotherapy due to the high heterogeneity of gastric cancer (GC). For patients receiving anti-PD-1 immunotherapy, elevated PD-L1 expression was correlated with prolonged PFS and OS, consistent with landmark trials including KEYNOTE-061 [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>] and KEYNOTE-062 [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>]. This notion was further supported by PD-L1 staining of mIF analysis. While PD-L1 expression demonstrates significant prognostic value in advanced G/GEJ cancer, our data suggest it should not be considered as a standalone predictive biomarker for immunotherapy response.</p>
<p id="Par64">The potential immune microenvironment [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>] on the prognostic impact of ICIs on gastric cancer, such as interferon (IFN) [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>], neutrophil-to-lymphocyte ratio (NLR) [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>], and specific genes like ARID1A [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>], POLE or POLD1 [<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>], and TP53 [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>], have attracted significant attention in recent year. Interestingly, our mIF analysis revealed significantly greater CD8 + T cell infiltration in well responders versus poor responders, consistent with their established role as the key effector of antitumor immunity. However, the role of CD8 + T cells in the immunotherapy response remains unclear, which may be due to the functional heterogeneity of CD8 + T cell subtypes on one hand. Tc1 cells, which possess typical CD8 + T cell-related cytotoxic signatures, have been shown to promote the production of perforin, granzymes B and interferon(IFN)-γ [<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>] in order to kill tumor cells. Tc2 [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>] and Tc22 [<a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>] cells expressing granzyme B are highly cytolytic and demonstrate robust cytotoxic abilities. Tissue-resident memory T (TRM) cells, identified by CD103 (ITGAE) expression, correlate with improved survival [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]. Conversely, Tc9 and Tc17 subtypes [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>] have been shown to produce relatively little IFN-γ and granzyme B, and are thought to promote disease progression [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>–<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>]. In our mIF analysis, the prognosis of patients with high CD8 + T expression was significantly better than that of patients with low CD8 + T expression, suggesting that CD8 Tc subsets with strong cytotoxic functions such as Tc1s, Tc2s, or Tc22s account for the majority of the TME in our gastric cancer samples. However, no trials included in this analysis provided CD8 + T cell subset analysis, and the underlying predictive mechanism remains unclear and requires further investigation.</p>
<p id="Par65">On the other hand, some researchers have uncovered that a high degree of CD8 + T cell infiltration could increase the expression of immune checkpoint receptors such as PD-1 and CTLA-4 and sensitize tumors to ICI, which may be another reason for the good immunotherapy response of CD8 + T cells. Chiaravalli et al. [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>] established a positive correlation between CD8 + tumor-infiltrating lymphocytes (TILs), PD-L1 expression, and favorable clinical outcomes, supporting that CD8 + T cell-targeted strategies could potentiate the efficacy of anti-PD-1 immunotherapy. The immune checkpoint receptor CTLA-4 is expressed on CD8 + effector T cells, and CTLA-4 blockade enhances the response of CD8 + T cells in the TME [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]. Currently, the combination of anti-PD-1 and anti-CTLA-4 mAb (such as nivolumab plus ipilimumab) has been approved for the treatment of melanoma [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>], non-small cell lung cancer [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>], hepatocellular carcinoma [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>], mismatch repair deficient colorectal cancer [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>], while lack of sufficient evidence on advanced gastric cancer. The COMPASSION-04 clinical trial [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>] presented at 2024 American Association for Cancer Research (AACR) reported encouraging efficacy and safety profiles for cadonilimab, a PD-1/CTLA-4 bispecific antibody, in first-line G/GEJ adenocarcinoma regardless of PD-L1 status. Furthermore, several clinical trials of anti-CTLA immunotherapy for gastric cancer are still underway. Taken together, our results demonstrate that CD8 + T cells play a pivotal role in predicting ICI treatment responses. A combination of PD-1 and CTLA-4 blockade could have synergistic effects by potentiating the antitumor activity and provide more therapeutic options for patients with low PD-L1 expression, and, hopefully, to be a new first-line treatment option for gastric or GEJ adenocarcinoma.</p>
<p id="Par66">While numerous biomarkers have been identified for predicting response to ICIs in GC, the relationship between TME immune profiles and chemotherapy sensitivity remains poorly understood. Generally, chemotherapeutic drugs can specifically induce a cellular immune response, which results in tumor cell death or stimulates immune effector molecules to relieve the suppressed immune response. Therefore, tumor immune status can be used to evaluate the effects of chemotherapy. Interestingly, we observed that those with a CPS of 10 or more were more insensitive to chemotherapy and had significantly shorter PFS than patients with a CPS of less than 10. To further validate the association between PD-L1 expression and chemotherapy efficacy, we also analyzed the microenvironmental components using mIF analysis and found that elevated PD-L1 expression correlates with chemoresistance. Lou et al. [<a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>] used intracellular PD-L1 as an RNA-binding protein that enhances the efficacy of chemotherapy by inhibiting DNA damage response and repair. Another study by Frank Sinicrope [<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>] examined the potential role of tumor cell-intrinsic PD-L1 in regulating chemosensitivity in human CRC cells and found that the deletion of PD-L1 could suppress BH3-only BIM and BIK proteins, causing chemoresistance and survival reduction. In contrast to the ability of PD-L1 mentioned above, knockdown of PD-L1 has been shown to sensitize breast cancer [<a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>], small-cell lung cancer [<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>], and lymphoma cells [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>] to chemotherapy-induced apoptosis. This apparent contradiction may reflect the functional diversity of PD-L1 and tumor cell type specificity. In GC, Shin K et al. [<a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>] evaluated the correlation among serum-derived exoPD-L1, plasma sPD-L1, immune-related markers, and circulating immune cells and established sPD-L1 as a prognostic marker, with low sPD-L1 levels predicting better outcomes in chemotherapy-treated GC patients. In the tumor microenvironment, low PD-L1 expression also predicted sensitivity in our study. However, the limited existing literature on the role of PD-L1 against traditional chemotherapy highlight the need for the mechanistic studies.</p>
<p id="Par67">In addition, we found significantly higher expression of CD4 + T cells in the poor-responder group than in the well-responder group, suggesting that CD4 + T cell abundance may serve as a negative predictor of chemotherapy efficacy. Immunohistochemistry (IHC) of the T-cell marker CD4 + was performed on GC patients who received XELOX therapy to evaluate TILs at Fudan University [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>]. As a result, from patients in the XELOX non-sensitive group (XNSG), we observed that the percentage of CD4 positive cells was significantly higher than that in the XELOX sensitive group (XSG) (54.2% and 2.9%, respectively) (<em>P</em> &lt; 0.05). Similarly, the prognostic significance of CD4 + subsets was further supported by esophageal cancer (EC) studies demonstrating that Tregs - a specialized CD4 + population - negatively impact outcomes following chemoradiotherapy [<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>], which may be partially related to the expression of inhibitory receptors (such as IL-10) and depletion of T cells. Consequently, the density of CD4 + T cells may help stratify patients likely to benefit from platinum-based chemotherapy regimens. Despite the close association between CD4 + T cell density and chemotherapy response, the mechanism of chemoresistance in CD4 + Ts is far from fully understood. What’s more, the exploratory mIF analysis, while revealing significant associations between immune cell densities and treatment response, should be further validated in a large-scale sample due to the limited cohort size for subgroup stratification.</p></section><section id="Sec13"><h2 class="pmc_sec_title">Limitations</h2>
<p id="Par68">Despite its strengths and implications for future research, our study has some limitations. First and most importantly, combined with results from the ORIENT-16 clinical trial, the subgroup analyses regarding PD-L1 expression should be stratified based on CPS 0–5, 5–10 or CPS ≥ 10 for more precision treatment. There were a limited number of data and also a limited number of patients to allow meaningful analyses of this subgroup. Additionally, although we observed some significant tendency toward treatment response in patients with different components of the tumor microenvironment, the trend is still require further evaluation in larger patient populations. Finally, we only performed a quantitative analysis of each biomarker separately and only a single molecular marker for each cell type was used to identify immune cells in tumor tissue. Further studies, including colocalization analyses and spatial transcriptomics, are essential, with the potential to provide additional biological insights into the TME in GC and present an opportunity to improve patient selection for novel diagnostics and therapeutics.</p></section><section id="Sec14"><h2 class="pmc_sec_title">Conclusions</h2>
<p id="Par69">
In conclusion, we identified the predictive value of PD-L1 in both anti-PD-1 immunotherapy and platinum-based chemotherapy by further analyzing the survival curves stratified by PD-L1 expression and an interesting phenomenon was discovered by landmark statistical method that clear differences between anti-PD-1 immunotherapy and chemotherapy would display around 300 days after first-day treatment for patients with CPS &lt; 10. Multiplexed immunofluorescence exploration of the tumor microenvironment showed that immune cells such as CD4 and CD8 were closely correlated with therapy efficacy and would offer critical insights into the complex and heterogeneous immune landscape associated with immunotherapy and chemotherapy treatment response.</p></section><section id="Sec15"><h2 class="pmc_sec_title">Supplementary Information</h2>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12376434/bin/12885_2025_14805_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1.</a><sup> (859.7KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM2"><div class="media p"><div class="caption">
<a href="/articles/instance/12376434/bin/12885_2025_14805_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 2.</a><sup> (30.5KB, docx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>The authors declare that no external funding or assistance was received for this study.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>AACR</dt>
<dd><p id="Par6">American Association for Cancer Research</p></dd>
<dt>CIs</dt>
<dd><p id="Par7">Confidence Intervals</p></dd>
<dt>CR</dt>
<dd><p id="Par8">Complete Response</p></dd>
<dt>CPS</dt>
<dd><p id="Par9">Combined Positive Score</p></dd>
<dt>EC</dt>
<dd><p id="Par10">Esophageal Cancer</p></dd>
<dt>ECOG</dt>
<dd><p id="Par11">the Eastern Cooperative Oncology Group</p></dd>
<dt>GC</dt>
<dd><p id="Par12">Gastric Cancer</p></dd>
<dt>G/GEJ Cancer</dt>
<dd><p id="Par13">Gastric and Gastroesophageal Junction Cancer</p></dd>
<dt>HER2</dt>
<dd><p id="Par14">Human Epidermal Growth Factor Receptor 2</p></dd>
<dt>HRs</dt>
<dd><p id="Par15">Hazard Ratios</p></dd>
<dt>ICIs</dt>
<dd><p id="Par16">Immune Checkpoint Inhibitors</p></dd>
<dt>IFN</dt>
<dd><p id="Par17">Interferon</p></dd>
<dt>mIF</dt>
<dd><p id="Par18">multiplex Immunofluorescence</p></dd>
<dt>NK cell</dt>
<dd><p id="Par19">Natural Killer cell</p></dd>
<dt>NLR</dt>
<dd><p id="Par20">Neutrophil-to-Lymphocyte Ratio</p></dd>
<dt>NSCLC</dt>
<dd><p id="Par21">Non-Small Cell Lung Cancer</p></dd>
<dt>ORR</dt>
<dd><p id="Par22">Objective Response Rate</p></dd>
<dt>OS</dt>
<dd><p id="Par23">Overall Survival</p></dd>
<dt>PD-1/PD-L1</dt>
<dd><p id="Par24">Programmed Death-1/Programmed Death-ligand 1</p></dd>
<dt>PFS</dt>
<dd><p id="Par25">Progression-free Survival</p></dd>
<dt>PR</dt>
<dd><p id="Par26">Partial Response</p></dd>
<dt>PS score</dt>
<dd><p id="Par27">Performance Status score</p></dd>
<dt>RECIST guidelines</dt>
<dd><p id="Par28">Response Evaluation Criteria in Solid Tumors guidelines</p></dd>
<dt>SD</dt>
<dd><p id="Par29">Stable Disease</p></dd>
<dt>TILs</dt>
<dd><p id="Par30">Tumor-Infiltrating Lymphocytes</p></dd>
<dt>TME</dt>
<dd><p id="Par31">Tumor Microenvironment</p></dd>
<dt>TRM cells</dt>
<dd><p id="Par32">Tissue-resident Memory T cells</p></dd>
<dt>XNSG</dt>
<dd><p id="Par33">XELOX non-sensitive group</p></dd>
<dt>XSG</dt>
<dd><p id="Par34">XELOX sensitive group</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Authors’ contributions</h2>
<p>All authors contributed to the conception and design of this study. The ideas for this review have been provided by H.J. The clinical data was analyzed by H.W. and W.S., and the multiplex immunofluorescence was performed by H.W. and Q.L. Q.C. and Y.H. made the data curation, while Q.W., and D.H were responsible for data visualization. The first draft of the manuscript was written by H.W. and W.S., and H.J. and Y.D. critically revised the manuscript. All authors commented on the previous versions of the manuscript and approved the final manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This study is supported by grants from the Natural Science Foundation of Zhejiang Province (Grant No.: LMS25H160019) and Development Center for Medical Science and Technology National Health Commission of the People’s Republic of China (Grant No.: WKZX2024CX102213).</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>All data generated or analysed during this study are included in the supplementary data files.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par70">Our study was in accordance with the Good Clinical Practice Guideline and in compliance with the Helsinki Declaration. The study protocol was approved by the institutional Ethics Committee of the First Affiliated Hospital of College of Medicine, Zhejiang University, and was prospectively registered at ClinicalTrials (<a href="https://clinicaltrials.gov/ct2/show/NCT03745170" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03745170</a>). All patients provided written informed consent before enrollment.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par71">Not applicable.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par72">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher’s Note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
</cite> [<a href="https://doi.org/10.3322/caac.21660" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33538338/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sung%20H,%20Ferlay%20J,%20Siegel%20RL,%20Laversanne%20M,%20Soerjomataram%20I,%20Jemal%20A,%20et%20al.%20Global%20cancer%20statistics%202020:%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries.%20CA%20Cancer%20J%20Clin.%202021;71(3):209%E2%80%9349." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–12.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(12)60643-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23374478/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pennathur%20A,%20Gibson%20MK,%20Jobe%20BA,%20Luketich%20JD.%20Oesophageal%20carcinoma.%20Lancet.%202013;381(9864):400%E2%80%9312." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun. 2021;41(10):1037–48.</cite> [<a href="https://doi.org/10.1002/cac2.12197" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8504144/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34288593/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qiu%20H,%20Cao%20S,%20Xu%20R.%20Cancer%20incidence,%20mortality,%20and%20burden%20in%20China:%20a%20time-trend%20analysis%20and%20comparison%20with%20the%20United%20States%20and%20United%20Kingdom%20based%20on%20the%20global%20epidemiological%20data%20released%20in%202020.%20Cancer%20Commun.%202021;41(10):1037%E2%80%9348." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(14)70420-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25240821/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wilke%20H,%20Muro%20K,%20Van%20Cutsem%20E,%20Oh%20SC,%20Bodoky%20G,%20Shimada%20Y,%20et%20al.%20Ramucirumab%20plus%20paclitaxel%20versus%20placebo%20plus%20paclitaxel%20in%20patients%20with%20previously%20treated%20advanced%20gastric%20or%20gastro-oesophageal%20junction%20adenocarcinoma%20(RAINBOW):%20a%20double-blind,%20randomised%20phase%203%20trial.%20Lancet%20Oncol.%202014;15(11):1224%E2%80%9335." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(13)61719-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24094768/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fuchs%20CS,%20Tomasek%20J,%20Yong%20CJ,%20Dumitru%20F,%20Passalacqua%20R,%20Goswami%20C,%20et%20al.%20Ramucirumab%20monotherapy%20for%20previously%20treated%20advanced%20gastric%20or%20gastro-oesophageal%20junction%20adenocarcinoma%20(REGARD):%20an%20international,%20randomised,%20multicentre,%20placebo-controlled,%20phase%203%20trial.%20Lancet.%202014;383(9911):31%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.
</cite> [<a href="https://doi.org/10.1038/nature13480" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4170219/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25079317/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Comprehensive%20molecular%20characterization%20of%20gastric%20adenocarcinoma.%20Nature.%202014;513(7517):202%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(21)00797-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8436782/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34102137/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Janjigian%20YY,%20Shitara%20K,%20Moehler%20M,%20Garrido%20M,%20Salman%20P,%20Shen%20L,%20et%20al.%20First-line%20nivolumab%20plus%20chemotherapy%20versus%20chemotherapy%20alone%20for%20advanced%20gastric,%20gastro-oesophageal%20junction,%20and%20oesophageal%20adenocarcinoma%20(CheckMate%20649):%20a%20randomised,%20open-label,%20phase%203%20trial.%20Lancet.%202021;398(10294):27%E2%80%9340." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044–60.
</cite> [<a href="https://doi.org/10.3390/curroncol29050247" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9139602/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35621637/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shiravand%20Y,%20Khodadadi%20F,%20Kashani%20SMA,%20Hosseini-Fard%20SR,%20Hosseini%20S,%20Sadeghirad%20H,%20et%20al.%20Immune%20checkpoint%20inhibitors%20in%20cancer%20therapy.%20Curr%20Oncol.%202022;29(5):3044%E2%80%9360." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330(21):2064–74.
</cite> [<a href="https://doi.org/10.1001/jama.2023.19918" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10698618/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38051328/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20J,%20Jiang%20H,%20Pan%20Y,%20Gu%20K,%20Cang%20S,%20Han%20L,%20et%20al.%20Sintilimab%20plus%20chemotherapy%20for%20unresectable%20gastric%20or%20gastroesophageal%20junction%20cancer:%20the%20ORIENT-16%20randomized%20clinical%20trial.%20JAMA.%202023;330(21):2064%E2%80%9374." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–49.
</cite> [<a href="https://doi.org/10.1093/annonc/mdw350" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27664260/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Smyth%20EC,%20Verheij%20M,%20Allum%20W,%20Cunningham%20D,%20Cervantes%20A,%20Arnold%20D.%20Gastric%20cancer:%20ESMO%20clinical%20practice%20guidelines%20for%20diagnosis,%20treatment%20and%20follow-up.%20Ann%20Oncol.%202016;27(suppl%205):v38%E2%80%9349." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun. 2021;41(8):747–95.</cite> [<a href="https://doi.org/10.1002/cac2.12193" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8360643/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34197702/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20FH,%20Zhang%20XT,%20Li%20YF,%20Tang%20L,%20Qu%20XJ,%20Ying%20JE,%20et%20al.%20The%20Chinese%20society%20of%20clinical%20oncology%20(CSCO):%20clinical%20guidelines%20for%20the%20diagnosis%20and%20treatment%20of%20gastric%20cancer,%202021.%20Cancer%20Commun.%202021;41(8):747%E2%80%9395." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite> Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1–21.
</cite> [<a href="https://doi.org/10.1007/s10120-020-01042-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7790804/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32060757/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Japanese%20Gastric%20Cancer%20Association.%20Japanese%20gastric%20cancer%20treatment%20guidelines%202018%20(5th%20edition).%20Gastric%20Cancer.%202021;24(1):1%E2%80%9321." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(11):1467–82.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(17)30566-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5898242/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28958504/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Catenacci%20DVT,%20Tebbutt%20NC,%20Davidenko%20I,%20Murad%20AM,%20Al-Batran%20SE,%20Ilson%20DH,%20et%20al.%20Rilotumumab%20plus%20epirubicin,%20cisplatin,%20and%20capecitabine%20as%20first-line%20therapy%20in%20advanced%20MET-positive%20gastric%20or%20gastro-oesophageal%20junction%20cancer%20(RILOMET-1):%20a%20randomised,%20double-blind,%20placebo-controlled,%20phase%203%20trial.%20Lancet%20Oncol.%202017;18(11):1467%E2%80%9382." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490–9.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(13)70102-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23594786/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lordick%20F,%20Kang%20YK,%20Chung%20HC,%20Salman%20P,%20Oh%20SC,%20Bodoky%20G,%20et%20al.%20Capecitabine%20and%20cisplatin%20with%20or%20without%20cetuximab%20for%20patients%20with%20previously%20untreated%20advanced%20gastric%20cancer%20(EXPAND):%20a%20randomised,%20open-label%20phase%203%20trial.%20Lancet%20Oncol.%202013;14(6):490%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the metgastric randomized clinical trial. JAMA Oncol. 2017;3(5):620–7.
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2016.5580" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5824210/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27918764/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shah%20MA,%20Bang%20YJ,%20Lordick%20F,%20Alsina%20M,%20Chen%20M,%20Hack%20SP,%20et%20al.%20Effect%20of%20fluorouracil,%20leucovorin,%20and%20oxaliplatin%20with%20or%20without%20onartuzumab%20in%20HER2-negative,%20MET-positive%20gastroesophageal%20adenocarcinoma:%20the%20metgastric%20randomized%20clinical%20trial.%20JAMA%20Oncol.%202017;3(5):620%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Wang TT, Zhao YL, Peng LS, Chen N, Chen W, Lv YP, et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut. 2017;66(11):1900–11.
</cite> [<a href="https://doi.org/10.1136/gutjnl-2016-313075" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5739867/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28274999/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20TT,%20Zhao%20YL,%20Peng%20LS,%20Chen%20N,%20Chen%20W,%20Lv%20YP,%20et%20al.%20Tumour-activated%20neutrophils%20in%20gastric%20cancer%20foster%20immune%20suppression%20and%20disease%20progression%20through%20GM-CSF-PD-L1%20pathway.%20Gut.%202017;66(11):1900%E2%80%9311." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Huang YK, Wang M, Sun Y, Di Costanzo N, Mitchell C, Achuthan A, et al. Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry. Nat Commun. 2019;10(1):3928.
</cite> [<a href="https://doi.org/10.1038/s41467-019-11788-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6718690/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31477692/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang%20YK,%20Wang%20M,%20Sun%20Y,%20Di%20Costanzo%20N,%20Mitchell%20C,%20Achuthan%20A,%20et%20al.%20Macrophage%20spatial%20heterogeneity%20in%20gastric%20cancer%20defined%20by%20multiplex%20immunohistochemistry.%20Nat%20Commun.%202019;10(1):3928." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561–5.
</cite> [<a href="https://doi.org/10.1038/s41586-019-1914-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31942071/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cabrita%20R,%20Lauss%20M,%20Sanna%20A,%20Donia%20M,%20Skaarup%20Larsen%20M,%20Mitra%20S,%20et%20al.%20Tertiary%20lymphoid%20structures%20improve%20immunotherapy%20and%20survival%20in%20melanoma.%20Nature.%202020;577(7791):561%E2%80%935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Hedrick CC, Malanchi I. Neutrophils in cancer: heterogeneous and multifaceted. Nat Rev Immunol. 2022;22(3):173–87.
</cite> [<a href="https://doi.org/10.1038/s41577-021-00571-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34230649/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hedrick%20CC,%20Malanchi%20I.%20Neutrophils%20in%20cancer:%20heterogeneous%20and%20multifaceted.%20Nat%20Rev%20Immunol.%202022;22(3):173%E2%80%9387." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71.
</cite> [<a href="https://doi.org/10.1038/nature13954" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4246418/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25428505/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tumeh%20PC,%20Harview%20CL,%20Yearley%20JH,%20Shintaku%20IP,%20Taylor%20EJ,%20Robert%20L,%20et%20al.%20PD-1%20blockade%20induces%20responses%20by%20inhibiting%20adaptive%20immune%20resistance.%20Nature.%202014;515(7528):568%E2%80%9371." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 2018;128(10):4654–68.
</cite> [<a href="https://doi.org/10.1172/JCI99317" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6159991/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30198904/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hsu%20J,%20Hodgins%20JJ,%20Marathe%20M,%20Nicolai%20CJ,%20Bourgeois-Daigneault%20MC,%20Trevino%20TN,%20et%20al.%20Contribution%20of%20NK%20cells%20to%20immunotherapy%20mediated%20by%20PD-1/PD-L1%20blockade.%20J%20Clin%20Invest.%202018;128(10):4654%E2%80%9368." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, Lindblad KE, Maier B, Sia D, et al. β-Catenin activation promotes immune escape and resistance to Anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9(8):1124–41.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-19-0074" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6677618/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31186238/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ruiz%20de%20Galarreta%20M,%20Bresnahan%20E,%20Molina-S%C3%A1nchez%20P,%20Lindblad%20KE,%20Maier%20B,%20Sia%20D,%20et%20al.%20%CE%B2-Catenin%20activation%20promotes%20immune%20escape%20and%20resistance%20to%20Anti-PD-1%20therapy%20in%20hepatocellular%20carcinoma.%20Cancer%20Discov.%202019;9(8):1124%E2%80%9341." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Ye B, Fan J, Xue L, Zhuang Y, Luo P, Jiang A, et al. iMLGAM: integrated machine learning and genetic algorithm-driven multiomics analysis for pan-cancer immunotherapy response prediction. Imeta. 2025;4(2): e70011.
</cite> [<a href="https://doi.org/10.1002/imt2.70011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11995183/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40236779/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ye%20B,%20Fan%20J,%20Xue%20L,%20Zhuang%20Y,%20Luo%20P,%20Jiang%20A,%20et%20al.%20iMLGAM:%20integrated%20machine%20learning%20and%20genetic%20algorithm-driven%20multiomics%20analysis%20for%20pan-cancer%20immunotherapy%20response%20prediction.%20Imeta.%202025;4(2):%20e70011." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Zhang P, Wen B, Gong J, Liu Z, Zhang M, Zhou G, et al. Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair-associated signature. Environ Toxicol. 2024;39(5):2803–16.
</cite> [<a href="https://doi.org/10.1002/tox.24155" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38287713/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20P,%20Wen%20B,%20Gong%20J,%20Liu%20Z,%20Zhang%20M,%20Zhou%20G,%20et%20al.%20Clinical%20prognostication%20and%20immunotherapy%20response%20prediction%20in%20esophageal%20squamous%20cell%20carcinoma%20using%20the%20DNA%20damage%20repair-associated%20signature.%20Environ%20Toxicol.%202024;39(5):2803%E2%80%9316." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Zhang P, Wang D, Zhou G, Jiang S, Zhang G, Zhang L et al. Novel post-translational modification learning signature reveals B4GALT2 as an immune exclusion regulator in lung adenocarcinoma. J Immunother Cancer. 2025;13(2).</cite> [<a href="https://doi.org/10.1136/jitc-2024-010787" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11865799/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40010763/" class="usa-link">PubMed</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(16)00561-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5480242/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26952546/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rosenberg%20JE,%20Hoffman-Censits%20J,%20Powles%20T,%20van%20der%20Heijden%20MS,%20Balar%20AV,%20Necchi%20A,%20et%20al.%20Atezolizumab%20in%20patients%20with%20locally%20advanced%20and%20metastatic%20urothelial%20carcinoma%20who%20have%20progressed%20following%20treatment%20with%20platinum-based%20chemotherapy:%20a%20single-arm,%20multicentre,%20phase%202%20trial.%20Lancet.%202016;387(10031):1909%E2%80%9320." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A. 2019;116(20):9999–10008.
</cite> [<a href="https://doi.org/10.1073/pnas.1822001116" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6525547/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31028147/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kamada%20T,%20Togashi%20Y,%20Tay%20C,%20Ha%20D,%20Sasaki%20A,%20Nakamura%20Y,%20et%20al.%20PD-1(+)%20regulatory%20T%20cells%20amplified%20by%20PD-1%20blockade%20promote%20hyperprogression%20of%20cancer.%20Proc%20Natl%20Acad%20Sci%20U%20S%20A.%202019;116(20):9999%E2%80%9310008." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Hensler M, Kasikova L, Fiser K, Rakova J, Skapa P, Laco J, et al. M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer. J Immunother Cancer. 2020;8(2).</cite> [<a href="https://doi.org/10.1136/jitc-2020-000979" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7443306/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32819974/" class="usa-link">PubMed</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–58.
</cite> [<a href="https://doi.org/10.1038/s41591-018-0101-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30013197/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kim%20ST,%20Cristescu%20R,%20Bass%20AJ,%20Kim%20KM,%20Odegaard%20JI,%20Kim%20K,%20et%20al.%20Comprehensive%20molecular%20characterization%20of%20clinical%20responses%20to%20PD-1%20inhibition%20in%20metastatic%20gastric%20cancer.%20Nat%20Med.%202018;24(9):1449%E2%80%9358." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Markus H, Moehler KK, Arkenau H-T, Oh D-Y. Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus che motherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). 2023 ASCO GIAbstract 286. 2023.</cite>
</li>
<li id="CR31">
<span class="label">31.</span><cite>Zhao JJ, Yap DWT, Chan YH, Tan BKJ, Teo CB, Syn NL, et al. Low programmed Death-Ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J Clin Oncol. 2022;40(4):392–402.
</cite> [<a href="https://doi.org/10.1200/JCO.21.01862" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34860570/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao%20JJ,%20Yap%20DWT,%20Chan%20YH,%20Tan%20BKJ,%20Teo%20CB,%20Syn%20NL,%20et%20al.%20Low%20programmed%20Death-Ligand%201-expressing%20subgroup%20outcomes%20of%20first-line%20immune%20checkpoint%20inhibitors%20in%20gastric%20or%20esophageal%20adenocarcinoma.%20J%20Clin%20Oncol.%202022;40(4):392%E2%80%93402." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Gauci ML, Lanoy E, Champiat S, Caramella C, Ammari S, Aspeslagh S, et al. Long-term survival in patients responding to anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation. Clin Cancer Res. 2019;25(3):946–56.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-18-0793" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30297458/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gauci%20ML,%20Lanoy%20E,%20Champiat%20S,%20Caramella%20C,%20Ammari%20S,%20Aspeslagh%20S,%20et%20al.%20Long-term%20survival%20in%20patients%20responding%20to%20anti-PD-1/PD-L1%20therapy%20and%20disease%20outcome%20upon%20treatment%20discontinuation.%20Clin%20Cancer%20Res.%202019;25(3):946%E2%80%9356." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, et al. Continuous versus 1-Year Fixed-Duration nivolumab in previously treated advanced Non-Small-Cell lung cancer: checkmate 153. J Clin Oncol. 2020;38(33):3863–73.
</cite> [<a href="https://doi.org/10.1200/JCO.20.00131" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7676888/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32910710/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Waterhouse%20DM,%20Garon%20EB,%20Chandler%20J,%20McCleod%20M,%20Hussein%20M,%20Jotte%20R,%20et%20al.%20Continuous%20versus%201-Year%20Fixed-Duration%20nivolumab%20in%20previously%20treated%20advanced%20Non-Small-Cell%20lung%20cancer:%20checkmate%20153.%20J%20Clin%20Oncol.%202020;38(33):3863%E2%80%9373." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024;385:e078876.
</cite> [<a href="https://doi.org/10.1136/bmj-2023-078876" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38806195/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qiu%20MZ,%20Oh%20DY,%20Kato%20K,%20Arkenau%20T,%20Tabernero%20J,%20Correa%20MC,%20et%20al.%20Tislelizumab%20plus%20chemotherapy%20versus%20placebo%20plus%20chemotherapy%20as%20first%20line%20treatment%20for%20advanced%20gastric%20or%20gastro-oesophageal%20junction%20adenocarcinoma:%20RATIONALE-305%20randomised,%20double%20blind,%20phase%203%20trial.%20BMJ.%202024;385:e078876." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436–43.
</cite> [<a href="https://doi.org/10.1158/2326-6066.CIR-15-0064" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5012642/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25941355/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Emens%20LA,%20Middleton%20G.%20The%20interplay%20of%20immunotherapy%20and%20chemotherapy:%20harnessing%20potential%20synergies.%20Cancer%20Immunol%20Res.%202015;3(5):436%E2%80%9343." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Bersanelli M, Buti S, Giannarelli D, Leonetti A, Cortellini A, Russo GL, et al. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: the multicenter retrospective CLARITY study. Lung Cancer. 2020;150:123–31.
</cite> [<a href="https://doi.org/10.1016/j.lungcan.2020.10.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33130353/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bersanelli%20M,%20Buti%20S,%20Giannarelli%20D,%20Leonetti%20A,%20Cortellini%20A,%20Russo%20GL,%20et%20al.%20Chemotherapy%20in%20non-small%20cell%20lung%20cancer%20patients%20after%20prior%20immunotherapy:%20the%20multicenter%20retrospective%20CLARITY%20study.%20Lung%20Cancer.%202020;150:123%E2%80%9331." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, et al. Pembrolizumab versus Paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–33.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(18)31257-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29880231/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shitara%20K,%20%C3%96zg%C3%BCro%C4%9Flu%20M,%20Bang%20YJ,%20Di%20Bartolomeo%20M,%20Mandal%C3%A0%20M,%20Ryu%20MH,%20et%20al.%20Pembrolizumab%20versus%20Paclitaxel%20for%20previously%20treated,%20advanced%20gastric%20or%20gastro-oesophageal%20junction%20cancer%20(KEYNOTE-061):%20a%20randomised,%20open-label,%20controlled,%20phase%203%20trial.%20Lancet.%202018;392(10142):123%E2%80%9333." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571–80.
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2020.3370" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7489405/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32880601/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shitara%20K,%20Van%20Cutsem%20E,%20Bang%20YJ,%20Fuchs%20C,%20Wyrwicz%20L,%20Lee%20KW,%20et%20al.%20Efficacy%20and%20safety%20of%20pembrolizumab%20or%20pembrolizumab%20plus%20chemotherapy%20vs%20chemotherapy%20alone%20for%20patients%20with%20first-line,%20advanced%20gastric%20cancer:%20the%20KEYNOTE-062%20phase%203%20randomized%20clinical%20trial.%20JAMA%20Oncol.%202020;6(10):1571%E2%80%9380." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Wang J, Ma X, Ma Z, Ma Y, Wang J, Cao B. Research progress of biomarkers for immune checkpoint inhibitors on digestive system cancers. Front Immunol. 2022;13:810539.
</cite> [<a href="https://doi.org/10.3389/fimmu.2022.810539" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9043345/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35493526/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20J,%20Ma%20X,%20Ma%20Z,%20Ma%20Y,%20Wang%20J,%20Cao%20B.%20Research%20progress%20of%20biomarkers%20for%20immune%20checkpoint%20inhibitors%20on%20digestive%20system%20cancers.%20Front%20Immunol.%202022;13:810539." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(16)00587-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26970723/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fehrenbacher%20L,%20Spira%20A,%20Ballinger%20M,%20Kowanetz%20M,%20Vansteenkiste%20J,%20Mazieres%20J,%20et%20al.%20Atezolizumab%20versus%20docetaxel%20for%20patients%20with%20previously%20treated%20non-small-cell%20lung%20cancer%20(POPLAR):%20a%20multicentre,%20open-label,%20phase%202%20randomised%20controlled%20trial.%20Lancet.%202016;387(10030):1837%E2%80%9346." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6): dju124.
</cite> [<a href="https://doi.org/10.1093/jnci/dju124" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24875653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Templeton%20AJ,%20McNamara%20MG,%20%C5%A0eruga%20B,%20Vera-Badillo%20FE,%20Aneja%20P,%20Oca%C3%B1a%20A,%20et%20al.%20Prognostic%20role%20of%20neutrophil-to-lymphocyte%20ratio%20in%20solid%20tumors:%20a%20systematic%20review%20and%20meta-analysis.%20J%20Natl%20Cancer%20Inst.%202014;106(6):%20dju124." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Hu G, Tu W, Yang L, Peng G, Yang L. ARID1A deficiency and immune checkpoint blockade therapy: from mechanisms to clinical application. Cancer Lett. 2020;473:148–55.
</cite> [<a href="https://doi.org/10.1016/j.canlet.2020.01.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31911080/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hu%20G,%20Tu%20W,%20Yang%20L,%20Peng%20G,%20Yang%20L.%20ARID1A%20deficiency%20and%20immune%20checkpoint%20blockade%20therapy:%20from%20mechanisms%20to%20clinical%20application.%20Cancer%20Lett.%202020;473:148%E2%80%9355." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol. 2019;5(10):1504–6.
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2019.2963" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6696731/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31415061/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20F,%20Zhao%20Q,%20Wang%20YN,%20Jin%20Y,%20He%20MM,%20Liu%20ZX,%20et%20al.%20Evaluation%20of%20POLE%20and%20POLD1%20mutations%20as%20biomarkers%20for%20immunotherapy%20outcomes%20across%20multiple%20cancer%20types.%20JAMA%20Oncol.%202019;5(10):1504%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Zhong J, Pan R, Gao M, Mo Y, Peng X, Liang G, et al. Identification and validation of a T cell marker gene-based signature to predict prognosis and immunotherapy response in gastric cancer. Sci Rep. 2023;13(1):21357.
</cite> [<a href="https://doi.org/10.1038/s41598-023-48930-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10696024/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38049463/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhong%20J,%20Pan%20R,%20Gao%20M,%20Mo%20Y,%20Peng%20X,%20Liang%20G,%20et%20al.%20Identification%20and%20validation%20of%20a%20T%20cell%20marker%20gene-based%20signature%20to%20predict%20prognosis%20and%20immunotherapy%20response%20in%20gastric%20cancer.%20Sci%20Rep.%202023;13(1):21357." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Yang Y, Ochando JC, Bromberg JS, Ding Y. Identification of a distant T-bet enhancer responsive to IL-12/Stat4 and IFNgamma/Stat1 signals. Blood. 2007;110(7):2494–500.
</cite> [<a href="https://doi.org/10.1182/blood-2006-11-058271" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1988915/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17575072/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20Y,%20Ochando%20JC,%20Bromberg%20JS,%20Ding%20Y.%20Identification%20of%20a%20distant%20T-bet%20enhancer%20responsive%20to%20IL-12/Stat4%20and%20IFNgamma/Stat1%20signals.%20Blood.%202007;110(7):2494%E2%80%93500." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Kemp RA, Ronchese F. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol. 2001;167(11):6497–502.
</cite> [<a href="https://doi.org/10.4049/jimmunol.167.11.6497" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11714817/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kemp%20RA,%20Ronchese%20F.%20Tumor-specific%20Tc1,%20but%20not%20Tc2,%20cells%20deliver%20protective%20antitumor%20immunity.%20J%20Immunol.%202001;167(11):6497%E2%80%93502." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Zhang S, Fujita H, Mitsui H, Yanofsky VR, Fuentes-Duculan J, Pettersen JS, et al. Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma. PLoS One. 2013;8(5):e62154.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0062154" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3646982/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23667456/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20S,%20Fujita%20H,%20Mitsui%20H,%20Yanofsky%20VR,%20Fuentes-Duculan%20J,%20Pettersen%20JS,%20et%20al.%20Increased%20Tc22%20and%20Treg/CD8%20ratio%20contribute%20to%20aggressive%20growth%20of%20transplant%20associated%20squamous%20cell%20carcinoma.%20PLoS%20One.%202013;8(5):e62154." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Banchereau R, Chitre AS, Scherl A, Wu TD, Patil NS, de Almeida P et al. Intratumoral CD103 + CD8 + T cells predict response to PD-L1 Blockade. J Immunother Cancer. 2021;9(4).</cite> [<a href="https://doi.org/10.1136/jitc-2020-002231" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8032254/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33827905/" class="usa-link">PubMed</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Visekruna A, Ritter J, Scholz T, Campos L, Guralnik A, Poncette L, et al. Tc9 cells, a new subset of CD8(+) T cells, support Th2-mediated airway inflammation. Eur J Immunol. 2013;43(3):606–18.
</cite> [<a href="https://doi.org/10.1002/eji.201242825" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23254356/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Visekruna%20A,%20Ritter%20J,%20Scholz%20T,%20Campos%20L,%20Guralnik%20A,%20Poncette%20L,%20et%20al.%20Tc9%20cells,%20a%20new%20subset%20of%20CD8(+)%20T%20cells,%20support%20Th2-mediated%20airway%20inflammation.%20Eur%20J%20Immunol.%202013;43(3):606%E2%80%9318." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007;178(11):6730–3.
</cite> [<a href="https://doi.org/10.4049/jimmunol.178.11.6730" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17513719/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kryczek%20I,%20Wei%20S,%20Zou%20L,%20Altuwaijri%20S,%20Szeliga%20W,%20Kolls%20J,%20et%20al.%20Cutting%20edge:%20Th17%20and%20regulatory%20T%20cell%20dynamics%20and%20the%20regulation%20by%20IL-2%20in%20the%20tumor%20microenvironment.%20J%20Immunol.%202007;178(11):6730%E2%80%933." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Kuang DM, Peng C, Zhao Q, Wu Y, Zhu LY, Wang J, et al. Tumor-activated monocytes promote expansion of IL-17-producing CD8 + T cells in hepatocellular carcinoma patients. J Immunol. 2010;185(3):1544–9.
</cite> [<a href="https://doi.org/10.4049/jimmunol.0904094" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20581151/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kuang%20DM,%20Peng%20C,%20Zhao%20Q,%20Wu%20Y,%20Zhu%20LY,%20Wang%20J,%20et%20al.%20Tumor-activated%20monocytes%20promote%20expansion%20of%20IL-17-producing%20CD8%E2%80%89+%E2%80%89T%20cells%20in%20hepatocellular%20carcinoma%20patients.%20J%20Immunol.%202010;185(3):1544%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Zhuang Y, Peng LS, Zhao YL, Shi Y, Mao XH, Chen W, et al. CD8(+) T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with survival time of patients with gastric cancer. Gastroenterology. 2012;143(4):951–e628.
</cite> [<a href="https://doi.org/10.1053/j.gastro.2012.06.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22710190/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhuang%20Y,%20Peng%20LS,%20Zhao%20YL,%20Shi%20Y,%20Mao%20XH,%20Chen%20W,%20et%20al.%20CD8(+)%20T%20cells%20that%20produce%20interleukin-17%20regulate%20myeloid-derived%20suppressor%20cells%20and%20are%20associated%20with%20survival%20time%20of%20patients%20with%20gastric%20cancer.%20Gastroenterology.%202012;143(4):951%E2%80%93e628." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Chiaravalli AM, Feltri M, Bertolini V, Bagnoli E, Furlan D, Cerutti R, et al. Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection. Virchows Arch. 2006;448(3):344–53.
</cite> [<a href="https://doi.org/10.1007/s00428-005-0066-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16261379/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chiaravalli%20AM,%20Feltri%20M,%20Bertolini%20V,%20Bagnoli%20E,%20Furlan%20D,%20Cerutti%20R,%20et%20al.%20Intratumour%20T%20cells,%20their%20activation%20status%20and%20survival%20in%20gastric%20carcinomas%20characterised%20for%20microsatellite%20instability%20and%20Epstein-Barr%20virus%20infection.%20Virchows%20Arch.%202006;448(3):344%E2%80%9353." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543–53.
</cite> [<a href="https://doi.org/10.1128/MCB.25.21.9543-9553.2005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1265804/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16227604/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Parry%20RV,%20Chemnitz%20JM,%20Frauwirth%20KA,%20Lanfranco%20AR,%20Braunstein%20I,%20Kobayashi%20SV,%20et%20al.%20CTLA-4%20and%20PD-1%20receptors%20inhibit%20T-cell%20activation%20by%20distinct%20mechanisms.%20Mol%20Cell%20Biol.%202005;25(21):9543%E2%80%9353." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480–92.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(18)30700-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30361170/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hodi%20FS,%20Chiarion-Sileni%20V,%20Gonzalez%20R,%20Grob%20JJ,%20Rutkowski%20P,%20Cowey%20CL,%20et%20al.%20Nivolumab%20plus%20ipilimumab%20or%20nivolumab%20alone%20versus%20ipilimumab%20alone%20in%20advanced%20melanoma%20(CheckMate%20067):%204-year%20outcomes%20of%20a%20multicentre,%20randomised,%20phase%203%20trial.%20Lancet%20Oncol.%202018;19(11):1480%E2%80%9392." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III checkmate 227 trial. Eur J Cancer. 2019;116:137–47.
</cite> [<a href="https://doi.org/10.1016/j.ejca.2019.05.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31195357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Reck%20M,%20Schenker%20M,%20Lee%20KH,%20Provencio%20M,%20Nishio%20M,%20Lesniewski-Kmak%20K,%20et%20al.%20Nivolumab%20plus%20ipilimumab%20versus%20chemotherapy%20as%20first-line%20treatment%20in%20advanced%20non-small-cell%20lung%20cancer%20with%20high%20tumour%20mutational%20burden:%20patient-reported%20outcomes%20results%20from%20the%20randomised,%20open-label,%20phase%20III%20checkmate%20227%20trial.%20Eur%20J%20Cancer.%202019;116:137%E2%80%9347." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial. JAMA Oncol. 2020;6(11):e204564.
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2020.4564" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7530824/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33001135/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yau%20T,%20Kang%20YK,%20Kim%20TY,%20El-Khoueiry%20AB,%20Santoro%20A,%20Sangro%20B,%20et%20al.%20Efficacy%20and%20safety%20of%20nivolumab%20plus%20ipilimumab%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma%20previously%20treated%20with%20sorafenib:%20the%20checkmate%20040%20randomized%20clinical%20trial.%20JAMA%20Oncol.%202020;6(11):e204564." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(17)30422-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6207072/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28734759/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Overman%20MJ,%20McDermott%20R,%20Leach%20JL,%20Lonardi%20S,%20Lenz%20HJ,%20Morse%20MA,%20et%20al.%20Nivolumab%20in%20patients%20with%20metastatic%20DNA%20mismatch%20repair-deficient%20or%20microsatellite%20instability-high%20colorectal%20cancer%20(CheckMate%20142):%20an%20open-label,%20multicentre,%20phase%202%20study.%20Lancet%20Oncol.%202017;18(9):1182%E2%80%9391." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Gao X, Ji K, Jia Y, Shan F, Chen Y, Xu N, et al. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial. Nat Med. 2024;30(7):1943–51.
</cite> [<a href="https://doi.org/10.1038/s41591-024-03007-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38778212/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gao%20X,%20Ji%20K,%20Jia%20Y,%20Shan%20F,%20Chen%20Y,%20Xu%20N,%20et%20al.%20Cadonilimab%20with%20chemotherapy%20in%20HER2-negative%20gastric%20or%20gastroesophageal%20junction%20adenocarcinoma:%20the%20phase%201b/2%20COMPASSION-04%20trial.%20Nat%20Med.%202024;30(7):1943%E2%80%9351." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR60">
<span class="label">60.</span><cite>Tu X, Qin B, Zhang Y, Zhang C, Kahila M, Nowsheen S, et al. PD-L1 (B7-H1) competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy. Mol Cell. 2019;74(6):1215–e264.
</cite> [<a href="https://doi.org/10.1016/j.molcel.2019.04.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6737939/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31053471/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tu%20X,%20Qin%20B,%20Zhang%20Y,%20Zhang%20C,%20Kahila%20M,%20Nowsheen%20S,%20et%20al.%20PD-L1%20(B7-H1)%20competes%20with%20the%20RNA%20exosome%20to%20regulate%20the%20DNA%20damage%20response%20and%20can%20be%20targeted%20to%20sensitize%20to%20radiation%20or%20chemotherapy.%20Mol%20Cell.%202019;74(6):1215%E2%80%93e264." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR61">
<span class="label">61.</span><cite>Feng D, Qin B, Pal K, Sun L, Dutta S, Dong H, et al. BRAF(V600E)-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. Oncogene. 2019;38(41):6752–66.
</cite> [<a href="https://doi.org/10.1038/s41388-019-0919-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6786951/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31406255/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Feng%20D,%20Qin%20B,%20Pal%20K,%20Sun%20L,%20Dutta%20S,%20Dong%20H,%20et%20al.%20BRAF(V600E)-induced,%20tumor%20intrinsic%20PD-L1%20can%20regulate%20chemotherapy-induced%20apoptosis%20in%20human%20colon%20cancer%20cells%20and%20in%20tumor%20xenografts.%20Oncogene.%202019;38(41):6752%E2%80%9366." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR62">
<span class="label">62.</span><cite>Ghebeh H, Lehe C, Barhoush E, Al-Romaih K, Tulbah A, Al-Alwan M, et al. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res. 2010;12(4):R48.
</cite> [<a href="https://doi.org/10.1186/bcr2605" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2949635/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20626886/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ghebeh%20H,%20Lehe%20C,%20Barhoush%20E,%20Al-Romaih%20K,%20Tulbah%20A,%20Al-Alwan%20M,%20et%20al.%20Doxorubicin%20downregulates%20cell%20surface%20B7-H1%20expression%20and%20upregulates%20its%20nuclear%20expression%20in%20breast%20cancer%20cells:%20role%20of%20B7-H1%20as%20an%20anti-apoptotic%20molecule.%20Breast%20Cancer%20Res.%202010;12(4):R48." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR63">
<span class="label">63.</span><cite>Yan F, Pang J, Peng Y, Molina JR, Yang P, Liu S. Elevated cellular PD1/PD-L1 expression confers acquired resistance to cisplatin in small cell lung cancer cells. PLoS One. 2016;11(9):e0162925.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0162925" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5017656/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27610620/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yan%20F,%20Pang%20J,%20Peng%20Y,%20Molina%20JR,%20Yang%20P,%20Liu%20S.%20Elevated%20cellular%20PD1/PD-L1%20expression%20confers%20acquired%20resistance%20to%20cisplatin%20in%20small%20cell%20lung%20cancer%20cells.%20PLoS%20One.%202016;11(9):e0162925." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR64">
<span class="label">64.</span><cite>Liu J, Quan L, Zhang C, Liu A, Tong D, Wang J. Over-activated PD-1/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen. Oncol Lett. 2018;15(3):3321–8.
</cite> [<a href="https://doi.org/10.3892/ol.2017.7682" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5778856/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29435074/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20J,%20Quan%20L,%20Zhang%20C,%20Liu%20A,%20Tong%20D,%20Wang%20J.%20Over-activated%20PD-1/PD-L1%20axis%20facilitates%20the%20chemoresistance%20of%20diffuse%20large%20B-cell%20lymphoma%20cells%20to%20the%20CHOP%20regimen.%20Oncol%20Lett.%202018;15(3):3321%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR65">
<span class="label">65.</span><cite>Shin K, Kim J, Park SJ, Lee MA, Park JM, Choi MG, et al. Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy. Sci Rep. 2023;13(1):6952.
</cite> [<a href="https://doi.org/10.1038/s41598-023-33128-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10147600/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37117200/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shin%20K,%20Kim%20J,%20Park%20SJ,%20Lee%20MA,%20Park%20JM,%20Choi%20MG,%20et%20al.%20Prognostic%20value%20of%20soluble%20PD-L1%20and%20exosomal%20PD-L1%20in%20advanced%20gastric%20cancer%20patients%20receiving%20systemic%20chemotherapy.%20Sci%20Rep.%202023;13(1):6952." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR66">
<span class="label">66.</span><cite>Li Y, Xu C, Wang B, Xu F, Ma F, Qu Y, et al. Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies. Nat Commun. 2022;13(1):5723.
</cite> [<a href="https://doi.org/10.1038/s41467-022-33282-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9522856/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36175412/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20Y,%20Xu%20C,%20Wang%20B,%20Xu%20F,%20Ma%20F,%20Qu%20Y,%20et%20al.%20Proteomic%20characterization%20of%20gastric%20cancer%20response%20to%20chemotherapy%20and%20targeted%20therapy%20reveals%20new%20therapeutic%20strategies.%20Nat%20Commun.%202022;13(1):5723." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR67">
<span class="label">67.</span><cite>Lan F, Xu B, Li J. A low proportion of regulatory T cells before chemoradiotherapy predicts better overall survival in esophageal cancer. Ann Palliat Med. 2021;10(2):2195–202.
</cite> [<a href="https://doi.org/10.21037/apm-21-196" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33725774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lan%20F,%20Xu%20B,%20Li%20J.%20A%20low%20proportion%20of%20regulatory%20T%20cells%20before%20chemoradiotherapy%20predicts%20better%20overall%20survival%20in%20esophageal%20cancer.%20Ann%20Palliat%20Med.%202021;10(2):2195%E2%80%93202." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12376434/bin/12885_2025_14805_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1.</a><sup> (859.7KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12376434/bin/12885_2025_14805_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 2.</a><sup> (30.5KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>All data generated or analysed during this study are included in the supplementary data files.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from BMC Cancer are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s12885-025-14805-6"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/12885_2025_Article_14805.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (6.9 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12376434/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12376434/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12376434%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12376434/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12376434/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12376434/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40851062/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12376434/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40851062/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12376434/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12376434/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="0V1bGC26WSxKj1w10qVFP2aBVqi92aSPGcRko7Ny6UvDDRZghclCXhdfxl7ScVJR">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
